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ABSTRACT
Objective To estimate the potential population impact of
different screening strategies for identifying and treating
people at high risk of cardiovascular disease, including
strategies using routine data for cardiovascular risk
stratification, in light of the UK government’s
recommended national strategy to screen all adults aged
40-74 for cardiovascular risk.
Design Modelling study using data from a prospective
cohort, EPIC-Norfolk (European Prospective Investigation
of Cancer-Norfolk).
Setting An English county.
Participants16970menandwomenaged40-74andfree
from cardiovascular disease and diabetes at baseline.
Main outcome measures The main outcomes were the
population attributable fraction, the number needed to
screentopreventonenewcaseofcardiovasculardisease,
the number needed to treat to prevent one new case of
cardiovascular disease, and the number of new
cardiovascular events that could be prevented. Relative
risk reductions for estimated treatment effects were
derived from meta-analyses of clinical trials or guidelines
from the National Institute for Health and Clinical
Excellence.
Results 1362 cardiovascular events occurred over
183586 person years of follow-up. Compared with the
recommendedgovernmentstrategy,astepwisescreening
approach using a simple risk score incorporating routine
data could prevent a similar number (lower to upper
estimates) of new cardiovascular events annually in the
United Kingdom (26789, 20778 to 36239) and 25134
(19450 to 34134), respectively) but requiring only 60%
of the population to be invited to attend a vascular risk
assessment. A similar number of cardiovascular events
(25016, 19563 to 33372) could also be prevented by
inviting everyone aged 50-74 for a vascular assessment.
Using a participantcompleted Finnish diabetesrisk score
questionnaire or anthropometric cut-off points for risk
prestratification was less effective.
Conclusions Compared with the UK government’s
recommended national strategy to screen all adults aged
40-74 for cardiovascular risk, an approach using routine
data for cardiovascular risk stratification before inviting
people at high risk for a vascular risk assessment may be
similarly effective at preventing new cases of
cardiovascular disease, with potential cost savings.
INTRODUCTION
Primary prevention strategies have contributed to a
major decline in the incidence of cardiovascular dis-
easesincethe1990s.
1However,cardiovasculardisease
remains the leading cause of morbidity and mortality
in the United Kingdom.
2 It is estimated to cost the UK
economy £30bn (€34bn; $46bn) annually, about half
ofwhichisduetodirecthealthcarecosts.
3Inanattempt
toreducethe burdenofcardiovasculardiseasefurther,
the Department of Health has introduced a national
vascular risk screening programme to identify those
at high risk of cardiovascular disease.
45 All adults
aged40-74andfreeofdiabetesandcardiovasculardis-
ease and not being treated for hypertension who have
never been identified by self assessment or record
based screening will be invited to their surgery to
attend a health check, including blood pressure mea-
surement, blood tests, and cardiovascular risk assess-
ment before the consideration of interventions
appropriate to the level of risk.
5 It is estimated that
theprogrammehasthepotentialtoprevent9500myo-
cardial infarctions and strokes each year at an esti-
mated annual cost of £250m.
4 These figures are,
however, largely based on modelling studies using
cross sectional data, with several key assumptions.
67
The costs and benefits associated with mass screening
for cardiovascular disease are unknown.
89
Analternativeapproachtoinvitingalleligibleadults
for vascular risk screening might be to prestratify peo-
ple using routinedata before invitingthose at high risk
toattend forthe more invasiveandexpensive vascular
riskassessment.Thismayreducethenumberofpeople
requiredtoattendtheirsurgeryaswellasthecostofthe
screening programme. This stepwise approach may
also reduce the potential psychological harms, such
as anxiety and false reassurance, that have been asso-
ciated with screening tests.
10 Simple risk scores using
routine data have been shown to predict cardio-
vascular disease
1112 and all cause mortality.
1213
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might have a similar impact on the prevention of new
cases of cardiovascular disease compared with the
recommended strategy is unknown.
Population impact measures can be used to estimate
the effect of preventive strategies and interventions on
healthoutcomesatthepopulationlevel
14andarethere-
foreusefulforinformingpublichealthdecisionmaking.
Using data from a population based prospective UK
cohort, we modelled different screening strategies to
identify those at high risk of cardiovascular disease
and we examined the potential population impact of
each strategy by calculating the population attributable
fraction, the number needed to screen to prevent one
new caseof cardiovasculardisease, the number needed
to treat with lifestyle or drug interventions to prevent
onenewcaseofcardiovasculardisease,andthenumber
of new cardiovascular events that could be prevented.
METHODS
The European Prospective Investigation of Cancer-
Norfolk (EPIC-Norfolk) is a population based prospec-
tivestudyofmenandwomenaged40-79residinginthe
county of Norfolk, United Kingdom. Details of the
study have been described elsewhere.
15 Briefly,
between 1993 and 1997, 77630 adults were invited
from general practice to participate in the study. Of
these,25639(33.0%)consentedandattendedabaseline
health assessment. Participants completed question-
nairesabouttheirpersonalandfamilyhistoryofdisease,
drug use, and lifestyle, including smoking. Participants
were also asked whether a doctor had ever told them
thattheyhadanyoftheconditionsinalistthatincluded
diabetes, myocardial infarction (“heart attack”), and
stroke. Self reported physical activity was measured
usingtheEuropeanProspectiveInvestigationofCancer
physical activity questions,
16 which includes questions
on both occupational and recreational physical activity
as well as time spent in each activity. It has been vali-
dated against objectively measured physical activity.
16
Dietary behaviour was measured using a seven item
questionnaire on consumption of vegetables and
fruits.
17 Self reported consumption of these foods has
been associated with cardiovascular risk both in the
EPIC-Norfolkcohort
18andinothersimilarlongitudinal
studies.
1920 Anthropometric and blood pressure mea-
surements and non-fasting blood samples were also
taken at the health assessment.
People living in the Norfolk area are healthier than
the general UK population, with a standardised mor-
tality ratio of 93.
21 However, EPIC-Norfolk is similar
to a nationally representative sample for anthropo-
metric indices, blood pressure measurements, and
serum lipid levels.
15
We followed up participants who were free from
cardiovasculardiseaseanddiabetesatthetimeofrecruit-
ment,forthedevelopmentofafirstcardiovascularevent
or death. We report results for follow-up to 30 April
2007, a median of 10 years. Incident cardiovascular dis-
ease was defined as a composite of fatal or non-fatal
cardiovascular disease, including admission to hospital
for coronary heart disease or stroke, or death from cor-
onary heart disease, stroke, or peripheral vascular dis-
ease. We used the participants’ National Health
Servicenumbertodeterminetheirhospitalstaythrough
the East Norfolk Health Authority database, which
records all hospital contacts throughout England and
Wales for Norfolk residents. Vital status for all EPIC-
Norfolk participantswasobtained throughdeath certifi-
cation at the Office for National Statistics. Previous vali-
dation studies in this cohort indicated high specificity of
such case ascertainment.
22
Statistical analysis
Wesummarisedthe baselinecharacteristicsseparately
for men and women with and without cardiovascular
disease, using percentages for categorical data, means
for normally distributed data, and medians for non-
normally distributed data. We tested for differences
between groups using χ
2 tests for categorical variables
and t tests or Kruskal-Wallis tests for normally or non-
normally distributed continuous variables. To calcu-
late cardiovascular event rates we divided the number
ofsucheventsbypersonyearsoffollow-up.Follow-up
was defined as the period from the date of first health
assessment to the date of the first event (admission to
hospital or death), or 30 April 2007.
Modelling screening strategies
In keeping with guidelines proposed by the national
screeningcommittee,welimitedouranalysestopeople
aged 40-74 (779 people excluded) and excluded those
with a history of cardiovascular disease (n=1015), with
prevalent diabetes (n=704), and taking lipid lowering
drugs (n=241) or antihypertensive drugs, including
diuretics (n=3488). We tested the ability of screening
strategies incorporating different risk scores to identify
those at high risk of cardiovascular disease—the Fra-
mingham risk score,
11 the Cambridge diabetes risk
score,
23 and the Finnish diabetes risk score.
24 We used
the Cambridge risk score solely as an example of a risk
score using data routinely available in general practice
records,andtheFinnishdiabetesriskscore asanexam-
ple of a participant completed questionnaire (recom-
mended by the Department of Health as a first step for
identifying people at high risk, who will be offered test-
ing for fasting blood glucose). People with missing
valuesforoneormoreofthevariablesusedtocalculate
these scores were also excluded (n=2442), leaving
16970 people for analysis.
The Framingham risk score was derived using the
modified Framingham risk functions, recently updated
by D’Agostino et al.
11 The Cambridge risk score, a tool
developed in a British population to identify people at
risk of undiagnosed diabetes,
23 was derived using data
on age, sex, smoking, family history of diabetes, body
mass index, and prescribed steroids and anti-
hypertensivedrugs,variablesthatareroutinelyavailable
in primary care. We previously showed that this score
was effective at identifying people with diabetes who
havearaisedandpotentiallymodifiableriskofcoronary
heart disease,
25 and at predicting all cause mortality.
13
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tool, developed in a Finnish cohort, and includes age;
self reported use of antihypertensive drugs; history of
high blood glucose levels; physical activity of at least
four hours a week; daily consumption of vegetables,
fruits, and berries; and self reported body mass index
and waist circumference.
24 It has been shown to predict
incidentcoronaryheartdisease,stroke,andtotalmortal-
ity in a Finnish population.
12 The Department ofHealth
planstoincorporatethisriskscoreinthevascularscreen-
ingprogrammetoidentifypeoplewhoneedfurthertest-
ing of blood glucose levels.
4
We assumed that the response rate to the self admi-
nistered Finnish diabetes risk score questionnaire was
60%. We used a simple ordered index of overall phy-
sical activity derived from the baseline European Pro-
spective Investigation of Cancer physical activity
questions,
16 which is associated with incident cardio-
vascular disease and all cause mortality in the EPIC-
Norfolk cohort.
26 We used a simple seven item ques-
tion about consumption of vegetables and fruits to
examine whether participants in the cohort consumed
vegetables, fruit, or berries daily. As data on history of
high blood glucose levels were not available in EPIC-
Norfolk,we decidedtoexclude thisvariablein the cal-
culation of the Finnish diabetes risk score. We carried
out a sensitivity analysis for different response rates to
the Finnish diabetes risk score questionnaire (40% and
80%) and for its extreme cut-off points of 12 and 7,
assuming, respectively, that nobody had a history of
hyperglycaemia and that everyone had a history of
hyperglycaemia. We also carried out a sensitivity ana-
lysis to examine whether the population impact of the
strategies incorporating routine data (Cambridge risk
score) might change after excluding family history of
diabetes,smoking,or body massindex fromthe score.
We modelled seven different stepwise population
based strategies to screen for cardiovascular disease
(figure).
Stage 1: populations to be invited for vascular risk
assessment
 Strategy 1—all adults aged 40-74 (Department of
Health recommendation)
 Strategy 2—all adults aged 50-74
 Strategy 3—overweight adults (defined by body
mass index ≥27.5 kg/m
2 or a waist circumference
>94 cm in men and >80 cm in women)
 Strategy 4 (high risk approach using a participant
completed questionnaire)—adults with a score of
≥9 on the Finnish diabetes risk score
questionnaire
 Strategies 5-7 (high risk approach using routinely
available data)—adults ranked according to their
Yes
No (10 185: 513 (38%))†
EPIC-Norfolk (n=25 639)
Strategy 1
All adults aged 40-74
to general practice
Strategy 2
All adults aged 50-74
to general practice
Populations invited for
vascular risk assessment
Vascular risk
assessment
Strategy 4
(60% response)
FINDRISC score ≥9
Strategy 5
Top 20% of risk distribution:
Cambridge diabetes
risk score ≥0.2518
Strategy 6
Top 40% of risk distribution:
Cambridge diabetes
risk score ≥0.1194
Strategy 7
Top 60% of risk distribution:
Cambridge diabetes
risk score ≥0.0615
Strategy 3
Overweight adults (body
mass index ≥27.5 or waist
circumference >94 cm in
men, 80 cm in women)
EPIC-Norfolk cohort (n=16 970)
Exclusion criteria:
  Age <40 or ≥75 (n=779)
  History of cardivascular disease
    (n=1015)
  History of diabetes (n=704)
  Statin use (n=241)
  Antihypertensive use (n=3488)
  Missing data on body mass
    index, waist circumference,
    FINDRISC, Framingham risk
    score, and Cambridge diabetes
    risk score (n=2442) Interventions according to their
  risk stratification:
1) Smoking cessation
2) Exercise
3) Weight management
4) Antihypertensives
5) Statins
Yes
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
No (4464: 107 (8%))†
Framingham
risk score
≥0.20
Framingham
risk score
≥0.20
Framingham
risk score
≥0.20
Framingham
risk score
≥0.20
Framingham
risk score
≥0.20
Framingham
risk score
≥0.20
Framingham
risk score
≥0.20
Yes
No (8589: 522 (39%))†
Yes
No (10 630: 681 (50%))†
Yes
No (13 576: 857 (63%))†
Yes
No (6802: 222 (16%))†
‡
‡
‡
‡
‡
‡
‡
*
*
*
*
*
*
*
FINDRISC = Finnish diabetes risk score
* 75% attend for vascular risk assessment
† Numbers in parentheses are number of people not invited for vascular risk assessment, number of those who developed cardiovascular disease in this group (% of total)
‡ Stratified by obesity, smoking, hypertension, and high or low cardiovascular disease risk according to Framingham risk score with different rates of uptake, adherence, and
    relative risk reduction for each intervention
Schematic diagram of population based strategies to screen for cardiovascular disease, and subsequent interventions
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electronic general practice records; those in the
top 20%, 40%, and 60% of the risk distribution
would be invited
Stage 2
It was assumed that 75% of people invited would
attend a vascular risk assessment,
6 which would
include medical history taking, a physical examina-
tion, and blood tests, as recommended by the national
screening committee. These measurements would
then be used to calculate a Framingham risk score for
each participant. The national screening committee
recommendsthatthesepeoplewouldthenbestratified
into high and low risk groups according to their Fra-
mingham risk score (high risk: Framingham risk score
≥0.20), whetherthey were obese,hypertensive, or cur-
rent smokers. People would receive interventions
appropriate to their risk level, based on the assump-
tions of uptake, adherence,and relativerisk reduction,
as outlined in a recent report from the Department of
Health’s vascular team
6 (table 1). For example, some-
one who was obese, hypertensive, and had a Framing-
ham risk score ≥0.20 would be offered a weight
management programme and treatment with anti-
hypertensives and statins.
For each screening strategy we estimated the cumu-
lativeincidence rateof cardiovasculardisease,the sen-
sitivity or specificity, the area under the receiver
operating characteristic curve for the prediction of
cardiovascular disease, the population attributable
fraction, the number needed to screen to prevent one
newcaseofcardiovasculardisease,thenumberneeded
to treat to prevent one new case of cardiovascular dis-
ease, and the number of cardiovascular events that
could be prevented in the population.
3132 Sensitivity
is the proportion of those who developed cardio-
vascular disease who were correctly identified as
“high risk” by each screening strategy (combination
ofprestratificationandthenthesecondstepriskassess-
ment). Specificity refers to the proportion of the popu-
lation that did not experience a cardiovascular event
who were correctly identified as “low risk” by each
strategy. The area under the receiver operating char-
acteristic curve representsthe abilityof each screening
strategy to discriminate between those who did and
those who did not develop a cardiovascular event,
with a higher value suggesting better discriminatory
ability. The population attributable fraction quantifies
the contribution of each screening strategy to the pre-
ventionofcardiovasculardisease—thatis,itrepresents
theadditionalproportionofcardiovasculareventsthat
could be prevented in the population if a screening
strategy was implemented, compared with no screen-
ing strategy. After adults were stratified into groups
according to their level of cardiovascular risk, we
applied uptake and compliance rates and relative risk
reductionforeachpreventioninterventiontocalculate
thenumberofcardiovasculareventsthatcouldbepre-
vented in each group (box). The number of cardio-
vascular events that could be prevented in the
population is the sum of the number of cardiovascular
events that could be prevented in all the groups.
We also modelled the population impact for situa-
tionswhere65%and85%ofthoseinvitedwouldattend
a vascular risk assessment. For demonstrative pur-
poses,wealsocalculatedthenumberofcardiovascular
eventsthatcouldbepreventedinthepopulationforan
average primary care trust with a catchment area
including 136900 people aged 40-74 and for the UK
population,usingpopulationestimatesformid-2007.
33
Forthe purposeofmodellingthe populationimpact of
different cardiovascular disease screening strategies
and interventions, we made several assumptions
(box).Owingtouncertaintyconcerningtheinteraction
between multiple interventions, we also did a sensitiv-
ity analysis for the situation where there was no
Table 1 |Uptake, compliance, and relative risk reduction for interventions based on published
literature and expert opinion
6
Intervention Uptake (%) Compliance (%)
Relative risk reduction of
cardiovascular disease
Smoking cessation 19 15 0.36*
Antihypertensives 40 87 0.24†
Statins 85 70 0.31‡
Weight management 85 68 0.36§
*From meta-analysis on effect of smoking cessation on mortality and non-fatal cardiovascular disease.
27
†From NICE guidelines CG18 and CG34.
28
‡From NICE guideline TA94.
29
§From clinical trial of weight reducing diet and exercise.
30
Assumptions for modelling population impact of different population based screening
strategies for cardiovascular disease and primary prevention interventions
Everyone invited to a vascular assessment has an equal attendance rate (response rate
75%)
6
Risk of cardiovascular mortality is considered to be equal in those who do and those who
do not attend for screening
Nobody is receiving any intervention at baseline
If someone takes up two or more interventions, the relative risk will be multiplicative.
Therefore, combined relative risk can be calculated
6:
cardiovascular disease risk(new)=cardiovascular disease risk(prior)×(1−relative risk
reduction)int_1×(1−relative risk reduction)int_2×...×(1−relative risk reduction)int_n
Screening and interventions are assumed to occur only once
Adults who do not complete the intervention are assumed to have a cardiovascular risk
similar to those who never received an intervention
All lifestyle and drug interventions are independent of each other, so the rate of taking up
and adhering to one intervention does not have an effect on uptake and adherence to
another intervention
67
Accordingto thepreviousassumptions, thenumberofcardiovasculareventsthatcouldbe
prevented in the population can be calculated
3132:
number of cardiovascular events that could be prevented in the
population=N×cardiovascular disease rate(prior)×(1−((1−pt×pa×relative risk
reduction)int_1×(1−pt×pa×RRR)int_2×...×(1−pt×pa×relative risk reduction)int_n))
where N=number ofpeopleeligibleforreceiving multipleintervention; cardiovascular disease rate(prior)=background
cardiovascular disease rate without intervention; pt=proportion of peopletaking up intervention (uptake rate); pa=proportion
of peopleadhering to intervention (compliance); int_1=intervention 1; int_n=intervention n
Lowerand upperestimatesof the number ofcardiovascular events thatcouldbe prevented in the populationare calculatedby
applying point estimates ofpt, pa,and relative risk reduction to cardiovascular disease rate, with 95% confidence interval
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tiveriskreductionformultipleinterventionswasequal
to that of the single intervention with the largest risk
reduction.
RESULTS
Table 2 summarises the baseline characteristics of the
EPIC-Norfolk cohort. The median age of participants
was 56 years (interquartile range 49 to 64), and 7505
(44%) were men. Participants who developed cardio-
vascular disease during follow-up were older, more
obese, had higher blood pressure and cholesterol and
HbA1c levels, and had lower high density lipoprotein
cholesterol levels than those who did not develop
cardiovascular disease. They were less likely to be
moderately active or active and to consume vegetable
and fruits on a daily basis. The median values of the
Framingham and Cambridge risk scores were higher
in those who developed cardiovascular disease com-
pared with those who did not (Framingham risk score
0.21v0.10,P<0.001,Cambridgeriskscore0.17v0.08,
P<0.001). The Finnish diabetes risk score was also
higher in those who developed cardiovascular disease
(median score 8.5 v 7.0, P<0.001).
Overall, 1362 cardiovascular events occurred over
183586 person years of follow-up. The incidence rate
of cardiovascular disease was 7.4 per 1000 person
years. The incidence rate was higher in men than in
women (11.0, 95% confidence interval 10.2 to 11.7 v
4.7, 4.3 to 5.2 per 1000 person years). The incidence
rateinthosewithaFraminghamriskscoreof≥0.20was
19.4 (18.1 to 20.9) per 1000 person years, whereas in
those with a Framingham risk score of <0.20 it was 4.3
(4.0 to 4.7) per 1000 person years.
Table 3 shows for each strategy the number of peo-
ple who would need to be invited to a vascular risk
assessment, the risk of cardiovascular disease, the sen-
sitivity and specificity, and the predictive ability. If
adults aged 50 or more were invited to a vascular risk
assessment (strategy 2), three quarters of the total
population aged 40-74 would receive invitations.
About half the population would need inviting for
risk assessment if body mass index and waist circum-
ference cut-off points were used for risk
Table 2 |Baseline characteristics of EPIC-Norfolk cohort by cardiovascular disease (CVD) outcome and sex, 1993-2007. Values are numbers (percentages)
unless stated otherwise
Characteristics
Men Women
Did not develop CVD Developed CVD P value* Did not develop CVD Developed CVD P value*
No of participants 6634 871 8974 491
Median (interquartile range) age (years) 55 (49-63) 63 (55-68) <0.001 55 (49-63) 66 (58-70) <0.001
Social class†:
Professional 558 (8.5) 52 (6.1)
0.006
638 (7.3) 18 (3.8)
0.015
Managerial 2589 (39.5) 320 (37.5) 3257 (37.0) 173 (36.4)
Skilled, non-manual 781 (11.9) 107 (12.5) 1683 (19.1) 109 (22.9)
Skilled, manual 1642 (25.0) 210 (24.6) 1826 (20.8) 94 (19.8)
Semiskilled 823 (12.6) 131 (15.4) 1096 (12.5) 58 (12.2)
Non-skilled 163 (2.5) 33 (3.9) 296 (3.4) 23 (4.8)
Mean (SD) body mass index 26.1 (3.1) 26.7 (3.4) <0.001 25.7 (4.0) 26.4 (4.2) <0.001
Mean (SD) waist circumference (cm) 94.2 (9.2) 96.4 (9.8) <0.001 80.4 (10.0) 84.2 (10.5) <0.001
Mean (SD) systolic blood pressure (mm Hg) 134.2 (16.0) 142.4 (18.4) <0.001 130.5 (17.7) 140.1 (18.3) <0.001
Mean (SD) diastolicblood pressure(mm Hg) 83.3 (10.4) 86.7 (11.8) <0.001 79.6 (10.7) 83.6 (11.0) <0.001
Mean (SD) total cholesterol level (mmol/l) 5.9 (1.1) 6.3 (1.1) <0.001 6.2 (1.2) 6.7 (1.2) <0.001
Mean (SD) high density lipoprotein level
(mmol/l)
1.25 (0.33) 1.20 (0.32) 0.002 1.59 (0.44) 1.49 (0.42) <0.001
Mean (SD) HbA1c (%) 5.2 (0.6) 5.4 (0.8) <0.001 5.1 (0.6) 5.5 (0.8) <0.001
Smoking status:
Non-smoker 2468 (37.2) 239 (27.4) <0.001 5159 (57.5) 246 (50.1) <0.001
Former smoker 3375 (50.9) 477 (54.8) 2755 (30.7) 158 (32.2)
Current smoker 791 (11.9) 155 (17.8) 1060 (11.8) 87 (17.7)
Moderately active and active 3328 (50.2) 391 (44.9) 0.003 3804 (42.4) 149 (30.4) <0.001
Daily consumption of vegetables and fruits 3261 (49.2) 398 (45.7) 0.055 5818 (64.8) 281 (57.2) 0.001
Median (interquartile range) FINDRISC score 7 (4-10) 8 (6-11) <0.001 7 (4-10) 9 (6-11) <0.001
Median (interquartile range) diabetes risk
score
0.13 (0.07-0.27) 0.20 (0.11-0.42) <0.001 0.05 (0.02-0.13) 0.10 (0.05-0.27) <0.001
Median (interquartile range) Framingham
risk score
0.16 (0.10-0.25) 0.26 (0.18-0.35) <0.001 0.07 (0.04-0.12) 0.14 (0.09-0.21) <0.001
FINDRISC=Finnish diabetes risk score.
*Difference between people who developed cardiovascular disease and those who did not using t tests or Kruskal-Wallis tests for normally or non-normally distributed continuous variables
and χ
2 tests for categorical variables.
†Numbers do not add up to total as 290 people had missing data for this variable.
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egy using a participant completed questionnaire—Fin-
nish diabetes risk score cut-off point of ≥9 (strategy 4).
The strategies of inviting people aged 50-74 and using
routinedata(60%Cambridgeriskscore)werethemost
effective at identifying those who developed a first
cardiovascular event. Both strategies identified the
highest proportion of people who developed a first
cardiovascular event (92% and 83%, respectively). In
contrast, using a participant completed questionnaire
(strategy 4) identified 50% of those who developed a
cardiovascular event.
Inviting adults aged 50 or more (strategy 2) did not
compromise the sensitivity, specificity, or predictive
ability for cardiovascular events, compared with invit-
ing everyone (strategy 1). Strategy 7 also showed com-
parablesensitivityandspecificity,withasimilarability
to predict cardiovascular disease compared with strat-
egy 1: area under the receiver operating characteristic
curve 0.67 (95% confidence interval 0.65 to 0.68) and
0.67 (0.66 to 0.69), respectively. In contrast, inviting
people who are overweight and those at high risk
usingaparticipantcompletedquestionnaire(strategies
3 and 4) had significantly lower predictive abilities.
Table 4showsthepotentialpopulationimpactofthe
different screening strategies and subsequent treat-
ment options. The population attributable fraction
was greatest for strategies using age 50 or more and
routine data (60% Cambridge risk score) for identify-
ing people at risk, whereas inviting people who were
overweight and those at high risk using a participant
completed questionnaire (strategies 3 and 4) had the
lowest population attributable fractions. When using
the Cambridge risk score to rank people before invit-
ing those at high risk for a vascular risk assessment
(strategy5-7),boththepopulationattributablefraction
and the number of cardiovascular events that could be
preventedinthepopulationincreasedwiththeincreas-
ing number of people invited. Strategy 1 would pre-
vent the highest number of new cardiovascular events
Table 3 |Comparison of sensitivity, specificity, and predictive ability of different screening strategies for cardiovascular disease in EPIC-Norfolk cohort
Screening
strategy
No invited for risk
assessment
(%)
CVDeventsin
risk group
(%)
Person
years at
risk
Incidence of CVD per 1000
person years (95% CI) Sensitivity (%) (95% CI) Specificity (%) (95% CI) Area under ROC (95% CI)
Overall
Total 16 970 1362 183 586 7.42 (7.04 to 7.82) NA NA NA
Men 7505 871 79 517 10.95 (10.25 to 11.71)
Women 9465 491 104 068 4.72 (4.32 to 5.15)
Strategy 1: all adults
Total 16 970 (100) 1362 (100) 183 586 7.42 (7.04 to 7.82) 53.9 (51.2 to 56.6) 80.7 (80.1 to 81.3) 0.67 (0.66 to 0.69)
Men 7505 (100) 871 (100) 79 517 10.95 (10.25 to 11.71) 68.8 (65.6 to 71.8) 64.5 (63.3 to 65.7) 0.67 (0.65 to 0.68)
Women 9465 (100) 491 (100) 104 068 4.72 (4.32 to 5.15) 27.5 (23.6 to 31.7) 92.6 (92.1 to 93.2) 0.60 (0.58 to 0.62)
Strategy 2: age ≥ ≥50 years
Total 12 506 (74) 1255 (92) 134 276 9.35 (8.84 to 9.88) 52.6 (49.9 to 55.2) 82.0 (81.4 to 82.6) 0.67 (0.66 to 0.68)
Men 5641 (75) 793 (91) 59 099 13.42 (12.52 to 14.39) 66.8 (63.6 to 69.9) 65.6 (64.4 to 66.7) 0.66 (0.65 to 0.68)
Women 6865 (73) 462 (94) 75 177 6.15 (5.61 to 6.73) 27.3 (23.4 to 31.5) 92.7 (92.1 to 93.2) 0.60 (0.58 to 0.62)
Strategy 3: body mass index and waist circumference
Total 8381 (49) 840 (62) 89 282 9.41 (8.79 to 10.07) 35.1 (32.6 to 37.7) 87.5 (87.0 to 88.0) 0.61 (0.60 to 0.63)
Men 3895 (52) 532 (61) 40 530 13.13 (12.06 to 14.39) 43.1 (39.7 to 46.4) 77.8 (76.7 to 78.7) 0.60 (0.59 to 0.62)
Women 4486 (47) 308 (63) 48 753 6.32 (5.65 to 7.06) 21.0 (17.5 to 24.9) 94.7 (94.2 to 95.1) 0.58 (0.56 to 0.60)
Strategy 4: FINDRISC ≥ ≥9
Total 6340 (37) 681 (50) 67 154 10.14 (9.41 to 10.93) 29.9 (27.5 to 32.4) 89.0 (88.5 to 89.5) 0.59 (0.58 to 0.61)
Men 2812 (37) 413 (47) 28 985 14.25 (12.94 to 15.69) 35.2 (32.1 to 38.5) 80.7 (79.7 to 81.7) 0.58 (0.56 to 0.60)
Women 3528 (37) 268 (55) 38 169 7.02 (6.23 to 7.91) 20.4 (16.9 to 24.3) 95.1 (94.6 to 95.5) 0.58 (0.56 to 0.60)
Strategy 5: top 20% of CRS
Total 3394 (20) 505 (37) 35 049 14.41 (13.20 to 15.72) 26.1 (23.8 to 28.5) 91.8 (91.3 to 92.2) 0.59 (0.58 to 0.60)
Men 2176 (29) 374 (43) 22 191 16.85 (15.23 to 18.65) 34.6 (31.4 to 37.8) 84.3 (83.4 to 85.1) 0.59 (0.58 to 0.61)
Women 1218 (13) 131 (27) 12 858 10.19 (8.58 to 12.09) 11.0 (8.4 to 14.2) 97.3 (96.9 to 97.6) 0.54 (0.53 to 0.56)
Strategy 6: top 40% of CRS
Total 6785 (40) 849 (62) 71 162 11.93 (11.15 to 12.76) 41.6 (39.0 to 44.3) 85.6 (85.1 to 86.2) 0.64 (0.62 to 0.65)
Men 4088 (54) 625 (72) 42 164 14.82 (13.71 to 16.03) 55.9 (52.5 to 59.2) 71.7 (70.6 to 72.8) 0.64 (0.62 to 0.66)
Women 2697 (28) 224 (46) 28 998 7.72 (6.78 to 8.81) 16.3 (13.2 to 19.9) 95.9 (95.5 to 96.3) 0.56 (0.54 to 0.58)
Strategy 7: top 60% of CRS
Total 10 168 (60) 1140 (84) 107 939 10.56 (9.97 to 11.19) 52.0 (49.3 to 54.7) 81.7 (81.1 to 82.3) 0.67 (0.65 to 0.68)
Men 5875 (78) 802 (92) 61 512 13.04 (12.17 to 13.97) 67.4 (64.2 to 70.5) 65.3 (64.1 to 66.4) 0.66 (0.65 to 0.68)
Women 4293 (45) 338 (69) 46 427 7.28 (6.54 to 8.10) 24.6 (20.9 to 28.7) 93.8 (93.3 to 94.3) 0.59 (0.57 to 0.61)
FINDRISC=Finnish diabetes risk score; CRS=Cambridge diabetes risk score, ROC=receiver operating characteristic curve.
RESEARCH
page 6 of 11 BMJ | ONLINE FIRST | bmj.comwith a number of cardiovascular events that could be
preventedinthepopulationof16.9,whereasstrategies
2 and 7 had slightly lower values, of 15.7 and 15.8,
respectively. However, the number needed to attend
vascularriskassessmenttopreventonecardiovascular
event was lower for strategies 7 and 2 compared with
strategy 1 (482, 596, and 755, respectively). When
applying the number of cardiovascular events that
could be prevented in the population to the UK popu-
lation in mid-2007, 26789 new cardiovascular events
could be prevented each year if all adults aged 40-74
were invited for a vascular risk assessment, whereas
25134 new cases could be prevented if 60% of people
athighriskaccordingtotheCambridgeriskscorewere
invited for a vascular risk assessment.
Inasensitivityanalysis,whentheresponseratetothe
participant completed questionnaire (Finnish diabetes
riskscore)was40%,thenumberofnewcardiovascular
events that could be prevented was 6724, and when a
higherresponserateof80%wasachieved,thisstrategy
could prevent 13449 new cardiovascular events.
Using a Finnish diabetes risk score cut-off point of 7
ormore(assumingeveryonehadahistoryofhypergly-
caemia)identified70%ofthosewhodevelopedcardio-
vascular disease, and this approach could prevent
21114newcardiovascularevents.UsingaFinnishdia-
betes risk score cut-off point of 12 or more (equivalent
to the situation where nobody had a history of hyper-
glycaemia) identified only 18% of those who devel-
oped cardiovascular disease, and this strategy had the
lowest population attributable fraction and number of
cardiovascular events that could be prevented in the
population; only 7259 new cases could be prevented.
The number of new cardiovascular events that could
be prevented when attendance rates were changed
from 65% to 85% increased from 23217 to 30361
cases for the strategy inviting everyone, and from
21783 to 28485 cases for the high risk approach
usingroutinedata(60%Cambridgeriskscore).Finally,
excludingfamilyhistoryofdiabetes,smoking,orbody
mass index from the Cambridge risk score did not sig-
nificantly reduce the population impact of the strate-
gies using routine data as a prestratification tool.
When no additive effect between interventions was
Table 4 |Comparison of potential population impact of different cardiovascular disease (CVD) screening strategies and interventions in EPIC-Norfolk cohort
(n=16 970)
Screening strategy
Population
attributable
fraction (%)
No needed to attend
risk assessment to
prevent one new CVD
event
No needed to intervene
to prevent one new CVD
event
NEPP (lower to upper
estimates)
NEPP for average
primary care trust*
(lower to upper
estimates)
NEPP for United
Kingdom† (lower to
upper estimates)
Strategy 1: all adults
Total 100 755 107 16.9 (13.1 to 22.8) 136 (106 to 184) 26789(20778to36239)
Men 100 449 75 12.5 (10.1 to 16.0) 101 (81 to 129) 19904(16044to25377)
Women 100 1638 199 4.3 (3.0 to 6.8) 35 (24 to 55) 6885 (4734 to 10 862)
Strategy 2: age ≥ ≥50 years
Total 71 596 95 15.7 (12.3 to 21.0) 127 (99 to 169) 25016(19563to33372)
Men 65 360 68 11.8 (9.6 to 14.8) 95 (77 to 119) 18681(15192to23444)
Women 79 1291 176 4.0 (2.8 to 6.3) 32 (22 to 50) 6335 (4372 to 9927)
Strategy 3: body mass index and waist circumference
Total 25 527 100 11.9 (9.0 to 16.7) 96 (73 to 135) 18950(14332to26555)
Men 21 340 68 8.6 (6.8 to 11.3) 69 (55 to 91) 13637(10766to17879)
Women 30 1006 184 3.3 (2.2 to 5.5) 27 (18 to 44) 5313 (3566 to 8676)
Strategy 4: FINDRISC ≥ ≥9
Total 21 449 96 6.4 (4.8 to 9.0) 51 (38 to 73) 10 087 (7551 to 14 322)
Men 17 282 63 4.5 (3.5 to 5.9) 36 (28 to 48) 7124 (5577 to 9443)
Women 28 851 173 1.9 (1.2 to 3.1) 15 (10 to 25) 2962 (1962 to 4879)
Strategy 5: top 20% of CRS
Total 22 300 68 8.5 (6.2 to 12.3) 68 (50 to 99) 13 456 (9921 to 19 566)
Men 21 245 54 6.7 (5.1 to 9.0) 54 (41 to 73) 10 591 (8151 to 14 308)
Women 16 506 118 1.8 (1.1 to 3.3) 15 (9 to 27) 2865 (1770 to 5258)
Strategy 6: top 40% of CRS
Total 38 390 85 13.1 (10.0 to 18.0) 105 (80 to 146) 20731(15838to28659)
Men 40 298 63 10.3 (8.2 to 13.3) 83 (66 to 107) 16318(12979to21148)
Women 25 728 167 2.8 (1.8 to 4.7) 22 (15 to 38) 4413 (2859 to 7511)
Strategy 7: top 60% of CRS
Total 60 482 91 15.8 (12.2 to 21.5) 128 (99 to 173) 25134(19450to34134)
Men 65 362 69 12.2 (9.8 to 15.5) 98 (79 to 125) 19320(15553to24678)
Women 44 880 166 3.7 (2.5 to 6.0) 30 (20 to 48) 5814 (3897 to 9456)
NEPP=number of new CVD events that could be prevented; FINDRISC=Finnish diabetes risk score; CRS=Cambridge diabetes risk score.
*Catchment area 136 900 adults aged 40-74.
†26 954 900 adults aged 40-74.
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ventedforeachstrategywasreduced,butrelativecom-
parisons between strategies using routine data and the
strategy of inviting everyone remained unchanged.
DISCUSSION
Weestimatedthepotentialpopulationimpactofdiffer-
ent screening strategies for identifying people at high
risk of cardiovascular disease before lifestyle and drug
intervention. Compared with the recently recom-
mended programme by the national screening com-
mittee, our findings suggest that a similar number of
new cardiovascular events could be prevented by
using routine data to prestratify people before inviting
those at high risk to the more invasive and expensive
vascular risk assessment.
This approach has the potential to reduce the num-
ber of people required to attend their surgery for vas-
cular risk screening, as well as the cost of the screening
programme.Asimilarbenefitcouldalsobeachievedif
vascular risk assessments were limited to adults aged
50 or more.
Strategies using a participant completed question-
naire (Finnish diabetes risk score) or anthropometric
measuresasprestratificationtoolsseemtohavealesser
impact on primary prevention of cardiovascular dis-
ease at the population level.
Comparison with other studies
Although several studies have examined the impact of
a single intervention on prevention of cardiovascular
disease,
34-36 few studies have examined the population
impact of integrated multifactorial prevention strate-
gies on reducing the burden of cardiovascular disease.
A modelling study by Gemmell et al estimated the
population impact of strategies to prevent coronary
heart disease in England using aggregate data.
31 They
found that an estimated 4410 cases of coronary heart
diseasecouldbepreventedeachyearby lifestyleinter-
ventions and 2008 by drug interventions. These num-
bers are lower than our findings. This might be
explained by the individual level data used in our
study, which more closely represent real life situations
for population cardiovascular risk. Another explana-
tion might be the difference in the definition of out-
comes and the relative risk reduction estimates used
in each study.
Kahn et al used the Archimedes model to simulate
the population impact and cost effectiveness of 11
interventions for cardiovascular disease prevention in
theUSpopulation,usingindividualleveldatafromthe
nationalhealthandnutritioneducationsurvey.
37They
found that with feasible levels of performance and
effectiveness of implementing all prevention inter-
ventions together, 36% of myocardial infarctions and
20%ofstrokescouldbepreventedover30years.How-
ever, they did not consider screening procedures to
identify those at high risk and to whom interventions
should be targeted.
A modelling study by Marshall and Rouse
38 found
similar results to our own. They suggest that strategies
preselecting patients for risk assessment may reduce
staff timeand preventmore newcaseswithin available
resources, compared with inviting everyone. How-
ever, the authors used a hypothetical population,
assumingdefaultbloodpressureandbloodcholesterol
values for each individual, and calculated cardio-
vascular disease risk using the Framingham equations
to identify those at high risk who should be invited for
cardiovascular risk assessment.
The Department of Health has recently published a
report on the simulated population impact of various
vascular risk screening programmes.
7 The effects of
inviting different age groups and different intervals
for repeating vascular checks were modelled, includ-
ing a strategy to invite those at high risk for a vascular
assessment. They report the greatest benefits and cost
effectiveness for a strategy in which everyone aged 40-
74 was invited for a vascular check every five years
compared with other approaches. This contrasts with
our findings, which suggest that a strategy inviting
adults aged 50-74 or inviting just those identified as
high risk using routine data could prevent a similar
number of new cardiovascular events.
IntheDepartmentofHealthreport,theauthorsused
cross sectional data from the QRESEARCH database
and estimated cardiovascular risk using the QRISK
and the Framingham risk score.
67 Our study used
data from a prospective cohort, which allowed us to
use actual rates for cardiovascular disease events.
Moreover, not all risk factors for each individual
were measured in the QRESEARCH database, so the
authors used different datasets to simulate an indivi-
dual patient’s level of risk. Significant data were miss-
ingforsomeriskfactors—forexample,72%ofpatients
did not have data for cholesterol levels, and these
values were imputed.
6
Another explanation for the difference found
between our study and the Department of Health
report is our assumption that the offer of screening
and subsequent interventions would occur only once.
The Department of Health modelled screening and
interventions with phased implementation repeated
every five or 10 years and considered changes in risk
factors and cardiovascular risk over time.
67
Strengths and limitations of the study
We examined the potential population impact of dif-
ferent screening strategies and prevention inter-
ventions for cardiovascular disease in a large
population based cohort, using robust cardiovascular
diseaseoutcomesoveralongperiod.Weusedrelevant
measures of population impact such as the number
needed to screen and the number of events that could
be prevented in the population. Our modelling was
based on actual rates of cardiovascular disease with
associated 95% confidence intervals; key assumptions
wereinformedbyevidencefrommeta-analysesofclin-
ical trials and were subject to sensitivity analyses to
identify sources of uncertainty and to quantify their
contribution to overall uncertainty.
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ticapproach)forratesofuptake,compliance,andrela-
tive risk reduction, without accounting for uncertainty
of each estimate, limits insight into the range of these
intervention related variables and underestimates the
true uncertainty of the population impact. An alterna-
tive approachwould be to use probabilistic risk assess-
ment, which provides greater information on the
variability and uncertainty associated with health risk
and benefits by simultaneously accounting for the
uncertainty of multiple variables.
39
It is unlikely that people at different levels of cardio-
vascular risk have the same attendance rate. People at
high risk are less likely to attend for screening—for
example,oldermen are lesslikelyto attendfor screen-
ing than younger women.
40 We also assumed an equal
risk of cardiovascular mortality in those who did and
did not attend for screening, but previous studies have
shown that those who do attend have a significantly
lowermortalitythanthosewhodonotattend.
4142How-
ever, although these assumptions may affect the num-
ber ofeventsthat could be preventedthey are unlikely
to alter the main finding that prestratification using
routine data is more efficient than inviting all middle
aged members of the population for vascular risk
assessment.
Additionally, given the modest sensitivity of all the
proposed strategies, it is possible that people who are
not invited for assessment may be affected by adverse
psychological symptoms such as insecurity and anxi-
etyaboutthechanceofdevelopingthediseasebecause
they have been excluded from a screening
programme.
43
In our model, all interventions were understood to
act independently of each other, but in practice the
interaction between multiple lifestyle and drug inter-
ventions remains unclear. However, sensitivity analy-
sis assuming no additive effect of interventions did not
affect the relative performance of each screening strat-
egy. The incidence of cardiovascular disease in many
trials used to inform the assumptions for our model-
ling, particularly trials on lipid lowering,
44 is substan-
tially higher than the risk in our study. As such, the
reduction in cardiovascular risk associated with a par-
ticular intervention may not be fully achieved in this
low risk population. Therefore, the estimates of the
number of cardiovascular events that could be pre-
vented might have been overestimated.
Lastly,asparticipantsofEPIC-Norfolkarepredomi-
nantly white, the generalisability of our findings to
other ethnic groups and populations is limited. Ethni-
city might be an additional factor on which decisions
about how to invite high risk groups may be based.
Conclusions and policy implications
Understanding the balance between the benefits and
costs of a screening programme is crucial for public
health decision making. A universal screening pro-
gramme for cardiovascular disease might prevent an
important number of new cardiovascular events in a
population, but it may be unrealistic to implement in
increasingly resource constrained health systems. Pol-
icy makers have to decide on the balance between the
number of people needed to screen or treat and the
number of cases that can be prevented in the popula-
tion.
Although data on body mass index and waist cir-
cumference are relatively inexpensive to collect and
are increasingly available in primary care, using these
anthropometric data for risk prestratification would
fail to prevent many new cardiovascular events.
Astrategyusingtheparticipantcompletedquestion-
naire (Finnish diabetes risk score as an example) as a
prestratification tool would also have a relatively low
impactonthepreventionofcardiovasculardiseaseina
population. As non-responders to cardiovascular risk
assessment tend to be less healthy than responders,
41
the real population impact of this approach is likely
to be lower than our estimates. The Finnish diabetes
risk score questionnaire has not been validated in the
UKpopulationandalsorequiresnoveldatacollection.
Compared with the Department of Health recom-
mended screening programme, a similar number of
cardiovascular events could be prevented in the UK
population with a significantly lower number of adults
invited for a vascular risk assessment, through prestra-
tification using routine data. Our sensitivity analysis
further suggested that lower attendance rates would
result in a narrower gap in benefits between mass
screening and stepwise strategies using routine data,
which supports the use of routine data as prestratifica-
tion tools.
It is reassuring that the exclusion of a family history
of diabetes, smoking, and body mass index from the
Cambridge risk score did not adversely affect the
population impact of the strategies incorporating rou-
tine data, suggesting that the tool can be used in health
systemswheredataonthesevariablesarenotroutinely
collected.Similarly,theagerangeinvitedforscreening
could be adjusted—for example, from 40-74 years to
50-74 years.
These approaches might reduce the economic costs
and the potential psychological harm associated with
screeningtests.
10WeusedtheCambridgediabetesrisk
scoreasanexampleofa simpleriskscoreina stepwise
approach solelyfor demonstration.Alternativesimple
versionsofexistingtoolsspecificallydesignedtoassess
cardiovascular risk, such as QRISK,
45 might perform
better than a diabetes risk score. However, as with any
population based screening strategies based on histor-
ical cohort data, the policy would need to be reviewed
to keep pace with the changing patterns of risk factors,
treatments, and competing risks in the population.
Inconclusion,ourfindingsillustratethepotentialfor
using routinely available data for cardiovascular risk
stratification before inviting people at high risk to a
vascular assessment. Compared with mass screening,
this approach may be similarly effective at preventing
newcardiovasculareventsatthepopulationlevel,with
potential cost savings. This approach might also be
transferabletoresourcepoorhealthsystems.Although
the Finnish diabetes risk score may have a role in
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 9 of 11identifying people at risk of undiagnosed or incident
diabetes,it cannotbe recommendedfor use to identify
those at high cardiovascular risk in the United King-
dom. Further research on the cost effectiveness of dif-
ferentstepwisepopulationbasedscreeningstrategiesis
needed to inform future public health policy.
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